We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 12,106.00 | 12,120.00 | 12,122.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.55 | 187.67B |
Hot Features
Premium
RNS Number:6142H
AstraZeneca PLC
18 February 2003
RESEARCH UPDATE ON AZD3582
AstraZeneca and NicOx today announced that AZD3582, in development for the
treatment of acute and chronic nociceptive pain, showed efficacy in a recently
completed Phase II clinical study, but did not reach its primary end point with
respect to gastro-intestinal ulcers.
The majority of the secondary objectives, including protection against
gastro-intestinal damage (when ulcers and erosions are combined), were achieved
and overall AZD3582 was well tolerated.
AstraZeneca remains committed to the completion of the ongoing AZD3582 Phase II
development programme.
AstraZeneca, together with NicOx, will review the data generated from the
several ongoing AZD3582 Phase II clinical studies in the programme in order to
decide on the further development plans for AZD3582 and the CINOD class.
18 February 2003
Media Enquiries:
Emily Denney, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Relations:
Mina Blair Robinson, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESEAPAXFFXDEFE
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
